Ascletis Pharma (China) Co., Limited
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ascletis Pharma (China) Co., Limited sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Ascletis Pharma (China) Co., Limited: 6 sponsored US clinical trials, 2 recruiting.
Ascletis Pharma (China) Co., Limited sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Weight Management, with 2 trials.
Upper-quartile sponsor footprint
Ascletis Pharma (China) Co., Limited sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
NCT07321678
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
NCT07024602
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
NCT06679959
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07002905
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
NCT06972992
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity
NCT06680440
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Ascletis Pharma (China) Co., Limited pipeline
2 recruiting of 6 indexed (33% open); 3 completed (50%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Chronic Weight Management (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ascletis Pharma (China) Co., Limited: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Ascletis Pharma (China) Co., Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Ascletis Pharma (China) Co., Limited page
6 registered trials is a research-attention snapshot, not an endorsement of Ascletis Pharma (China) Co., Limited or any single study.
- 2 of Ascletis Pharma (China) Co., Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chronic Weight Management is the condition Ascletis Pharma (China) Co., Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Weight Management trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ascletis Pharma (China) Co., Limited pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.